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Abstract
Background: Activation of the mammalian Ras-Raf-MEK-ERK MAPK signaling cascade promotes cellular proliferation,
and activating Ras mutations are implicated in cancer onset and maintenance. This pathway, a therapeutic target of
interest, is highly conserved and required for vulval development in C. elegans. Gain-of-function mutations in the Ras
ortholog lead to constitutive pathway signaling and a multivulva (Muv) phenotype. MCP compounds were identified
in a yeast two-hybrid screen for their ability to disrupt Ras-Raf interactions. However, this had not been confirmed in
another system, and conflicting results were reported regarding selective MCP-mediated blockade of Ras- and Raf-
mediated biological activities in mammalian cells. Here we used the easily-scored Muv phenotype as an in vivo
readout to characterize the selectivity of MCP110 and its analogs, and performed biochemical studies in mammalian
cells to determine whether MCP treatment results in impaired interaction between Ras and its effector Raf.
Results: Our genetic analyses showed significant dose-dependent MCP-mediated reduction of Muv in C. elegans
strains with activating mutations in orthologs of Ras (LET-60) or Raf (LIN-45), but not MAP kinases or an Ets-like
transcription factor. Thus, these inhibitors selectively impair pathway function downstream of Ras and upstream of
or at the level of Raf, consistent with disruption of the Ras/Raf interaction. Our biochemical analyses of MCP110-
mediated disruption of Ras-Raf interactions in mammalian cells showed that MCP110 dose-dependently reduced
Raf-RBD pulldown of Ras, displaced a fluorescently-tagged Raf-RBD probe from plasma membrane locations of
active Ras to the cytosol and other compartments, and decreased active, phosphorylated ERK1/2.
Conclusions: We have effectively utilized C. elegans as an in vivo genetic system to evaluate the activity and
selectivity of inhibitors intended to target the Ras-Raf-MAPK pathway. We demonstrated the ability of MCP110 to
disrupt, at the level of Ras/Raf, the Muv phenotype induced by chronic activation of this pathway in C. elegans. In
mammalian cells, we not only demonstrated MCP-mediated blockade of the physical interaction between Ras and
Raf, but also narrowed the site of interaction on Raf to the RBD, and showed consequent functional impairment of
the Ras-Raf-MEK-ERK pathway in both in vivo and cell-based systems.
Background
Over the past two decades, there have been many
attempts to isolate and characterize pharmacological
inhibitors targeting Ras-dependent signaling pathways.
The small GTPase Ras normally transmits signals down-
stream of diverse inputs and is a critical signaling node
for many cellular activities. Aberrant Ras activity leads to
the deregulation of numerous cellular processes includ-
ing proliferation, survival, cell adhesion and migration,
that in turn can contribute to cellular transformation,
invasion and metastasis [1], and Ras is mutationally acti-
vated in ~30% of cancers [2]. Among the downstream
effectors of Ras, the most well-characterized is the Ras-
Raf-MAPK signaling pathway, in which Ras interaction
with the serine/threonine kinase Raf causes a cascade of
kinase activation, with Raf activating the mitogen-acti-
vated protein kinase kinases (MAPKK, or MEK) and
MEK activating the ERK MAPK, which then translocates
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to the nucleus to phosphorylate and activate transcrip-
tion factors to carry out the commands of Ras. The B-Raf
isoform is mutationally activated, most commonly at
V600E, in tumors including colorectal cancer, malignant
melanoma and thyroid cancer [3,4], in a manner
mutually exclusive with oncogenic Ras. Aberrant activa-
tion of MAPK has also been associated with various can-
cers [5]. Given the relevance of the Ras-Raf-MAPK
signaling pathway to a wide array of malignancies, there
has been a great deal of interest in developing anti-cancer
therapeutics by targeting specific elements of this path-
way [6-9]. Despite intensive efforts [10], it has proven
very difficult to selectively target Ras itself, which at pre-
sent is widely viewed as “undruggable” due to the pico-
molar affinity of GTP for Ras. Pharmacological inhibition
of the Raf and MEK kinases has been seen as more tract-
able, and several putative Raf inhibitors have reached
clinical trials, including both antisense and kinase inhibi-
tors. The most prominent of these, BAY43-9006 (sorafe-
nib), was originally described as a Raf kinase inhibitor
[11,12], but its activity in cancer patients did not corre-
late with Raf activation or mutational status. Instead, it
demonstrated additional activity towards the pro-angio-
genic vascular endothelial growth factor receptors
(VEGFR)-2 and -3, and to other receptor tyrosine kinases
such as PDGFR-beta that are also involved in tumorigen-
esis [13,14]. Thus, the anti-tumor effects of sorafenib,
now known as a “multikinase inhibitor”, are at least
partly mediated by blockade of VEGFR kinase rather
than Raf kinase. Newer Raf kinase inhibitors such as
PLX4032 [15] and its later derivatives, intended to be
selective for mutationally activated B-Raf (V600E), are
also under development [16]. Extensive investment has
also been made in MEK inhibitors including CI-1040,
AZD6244 and others [6,8,9,17], although none has yet
proven efficacious as single agent therapy.
Another approach to inhibit the Ras-Raf-MAPK sig-
naling pathway is through protein-protein interaction
(PPI) inhibitors such as those intended to disrupt the
interaction between the small GTPase Ras and the ser-
ine/threonine kinase Raf [6]. Here, we characterized the
activity of a novel family of putative Ras/Raf interaction
inhibitors derived from such a search. MCP compounds
such as MCP1 were originally isolated from a small
molecule library using a dual-bait two-hybrid system to
probe the interaction between Ras and Raf [18-20]. The
more advanced MCP110 and MCP116 as well as a very
weakly active analog MCP122 were synthesized during
optimization efforts. Earlier reports characterizing the
activity of these agents showed their ability to inhibit
Ras signaling and Ras-mediated cell proliferation and
anchorage-independent growth in cell-based systems, as
well as transformed growth in nude mouse xenografts
[20-22]. However, the mechanism of action of these
putative Ras/Raf interaction inhibitors is not completely
understood. The ability of MCP1 and later analogs such
as MCP110 to inhibit Ras- but not Raf-mediated trans-
formation in fibroblasts, colorectal cancer cell lines and
melanoma cell lines suggested that their action was at
the level of Ras rather than Raf, but more recent evi-
dence indicated that MCP compounds also have activity
towards melanoma cell lines in which B-Raf is mutated
[23]. Therefore it is unclear whether the anti-transfor-
mation activity of MCP compounds is due to blocking
Ras, Raf or yet another target. Whether MCP com-
pounds directly disrupt the physical interaction between
Ras and Raf, as shown by the yeast two-hybrid assay in
which they were originally identified, has not been con-
firmed in mammalian cells.
Characterizing the precise mechanism of action of PPI
inhibitors is a challenging task, especially given the diffi-
culty of determining whether a given compound is inter-
acting with the interface of one protein versus the other.
There are no structural analyses available to reveal
whether MCP compounds bind physically to Ras, to Raf,
or to both. We therefore set out to determine at what
level in the pathway MCP compounds act, by using
epistasis analyses in the nematode Caenorhabditis ele-
gans, a tractable genetic model system for the in vivo
evaluation of Ras pathway drug activity.
C. elegans has served as a very useful model organism
to study development, neurobiology and many other
biological processes. Recently it has also been useful in
pharmacogenetic studies to identify the targets of phar-
macological agents [24]. The C. elegans Ras-Raf-MAPK
signaling pathway is highly conserved, from the EGF
ligand to the transcriptional output [25,26]. LET-60, the
C. elegans ortholog of Ras, is critical to regulate vulval
development [27], and excessive activation at any level
of the pathway results in hyperinduction of vulval tissue,
leading to a Multivulva (Muv) phenotype. For example,
a glycine to glutamic acid mutation at residue 13
(G13E) of LET-60/Ras, results in a gain-of-function that
produces a constitutively activated LET-60 protein, ana-
logous to the well known Ras(G12V) mutation in mam-
malian cells. Not surprisingly, then, LET-60(G13E) is
well documented to induce the Muv phenotype [27], as
do transgenes bearing activated Raf (LIN-45) or MEK/
MAPK (MEK-2/MPK-1) and loss-of-function mutations
in the downstream Ets-like transcription factor LIN-1
[28-30]. Previous work by our group and others has vali-
dated these transgenes and the Muv phenotype of
C. elegans as in vivo readouts to evaluate the activity of
pharmacological inhibitors of the Ras-Raf-MEK-ERK
pathway [25,31] and to identify pharmacological targets
[24]. We therefore selected this system to characterize
the activity and selectivity of known and novel MCP
compounds.
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We first confirmed that MCP110 acts downstream of
Ras/LET-60 and upstream or at the level of Raf/LIN-45,
as would be expected for an inhibitor of the Ras/Raf
interaction. In addition, we demonstrate here that of
two previously uncharacterized MCP110 analogs,
MCP116, but not MCP146, also inhibits Ras/LET-60
signaling and displays specificity comparable to
MCP110. Finally, for the first time we show evidence in
mammalian cells that MCP110 disrupts not only signal-
ing from Ras to ERK but also the physical interaction
between Ras and Raf, and have narrowed the interface
on Raf to the Ras-binding domain.
Results
The C. elegans Ras signaling pathway as a platform for
analysis of small molecule inhibitors
We have previously established the multivulva (Muv)
phenotype of the nematode worm C. elegans as an in
vivo model system to study the action of pharmacologi-
cal inhibitors targeting Ras-induced signaling cascades.
Specifically, we used the well-characterized selective
MEK inhibitor U0126 to demonstrate that effective
pharmacological inhibition of the Ras-Raf-MEK path-
ways restored a normal phenotype in animals that
would otherwise display a Muv phenotype based on
their genetic background [25]. The Ras-Raf signal that
controls vulval cell fate in C. elegans is well described at
the molecular genetic level. Consequently, many genetic
reagents, including both in situ mutations and trans-
genic constructs, are available for pharmacological dis-
section of the Ras pathway. In this study, we exploited
activated Ras, activated Raf, combined activated MEK/
ERK, and loss of an Ets transcription factor, all of which
result in excessive vulval induction. For clarity we refer
to these four reagents, which are described further in
the Methods section, as Ras, RafAA, MEK/ERK and Ets.
In this system, wild type animals have normal vulvae
accompanied by no ventral protrusions. In contrast, ani-
mals with excessive Ras pathway activity display hyperin-
duction of epithelial cells that results in a Muv phenotype,
characterized by ectopic nonfunctional pseudovulvae that
are visible as ventral protrusions. Both phenotypes can be
scored under a dissecting stereomicroscope, and can be
quantified either in a binary manner as Muv or non-Muv
(WT), or by the number (0-3) of ectopic pseudovulvae.
Thus, animals with one or more ventral protrusions are
scored as Muv, whereas those with a fully developed vulva
but no protrusions are scored as wild type. The conse-
quences of drug treatment can be quantified precisely by
scoring the phenotypes of animals whose vulval develop-
ment proceeds in the presence of the pharmacological
inhibitor [25]. Here we used this validated system to test
the activity and target selectivity of small molecules that
are putative Ras/Raf interaction inhibitors, MCP110
[18-20] and its novel analogs MCP116 and MCP146.
To illustrate the phenotypes described above and
quantitated in our study, we show images of animals
grown under different drug conditions (Figure 1A).
Wild-type animals have a normal vulva (arrowhead) and
an undisrupted ventral surface. Animals expressing acti-
vated Ras display the expected Muv phenotype when
treated with vehicle (DMSO) only; both the functional
vulva (arrowhead) and three additional ventral protru-
sions (arrows) are identifiable. In contrast, activated Ras
animals treated with MCP110 do not display the typical
Ras-induced Muv phenotype, but rather have a single
properly developed vulva and no protrusions. Thus,
MCP-treated Ras animals have the same appearance as
wild type animals, consistent with depressed Ras-Raf-
MEK-ERK signaling [25,31].
MCP110 and MCP116, putative Ras/Raf interaction
inhibitors, reverse the hyper-induced Muv phenotype
conferred by activated Ras
We scored the Muv phenotype of activated Ras animals
grown in the presence of MCP inhibitors or DMSO
vehicle. Developmentally synchronous animals were col-
lected from each treatment group (see Methods for
details) and the Muv phenotype scored according to the
presence and number of ectopic pseudovulvae. Animals
displaying a Muv phenotype when drug-treated were
normalized to the level of hyper-induction of Muv seen
in vehicle-treated animals, with the baseline for Muv
established separately for each genotype.
We expected the Muv phenotype to be sensitive to
MCP compounds if the Ras-Raf interaction was success-
fully inhibited, and therefore that treated animals would
display normal vulval development. As expected, we
observed (Fig. 1B) that animals expressing activated Ras/
LET-60 treated with MCP110 (20 μM) were approxi-
mately 50% less likely than vehicle-treated animals to
display a Muv phenotype. Delivery to these animals
of drug concentrations higher than 20 μM was not pos-
sible due to MCP compound precipitation. Additionally,
we observed that the previously uncharacterized
MCP110 analog, MCP116, showed inhibitory activity
similar to that of MCP110. Effects of both MCP110 and
MCP116 were dose-dependent. In contrast, a third deri-
vative, MCP146, showed no significant activity at any
tested concentration. As an additional negative control,
we show that treatment with the poorly active analog
MCP122 [20,21,23] had no effect. Together, these
results indicate that both MCP110 and MCP116 inhibit
the Ras-Raf-MAP kinase pathway downstream of
Ras activation. This conclusion is consistent with
the reported ability of MCP110 to inhibit Ras/Raf
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interactions in yeast and with its biological activities in
mammalian cells.
MCP compound inhibition of the Muv phenotype is
specific to the Ras pathway
We have shown previously [25] that the well-character-
ized MEK inhibitor U0126 suppressed the activated Ras
Muv phenotype, but not the Muv phenotype conferred
by loss of the Ets-like transcription factor. Therefore, as
a control for pathway specificity, to ensure that MCP-
mediated suppression of the Muv phenotype was not
indirect, for example by inhibiting the cell cycle, we
tested whether MCP compounds also inhibited the Muv
phenotype of Ets animals. As expected, Ets animals were
resistant to both MCP110 and MCP116, with no
response at any dose (Figure 2A).
MCP compounds act upstream of MEK
To determine the pathway level at which MCP com-
pounds act, we continued our analysis with MEK/ERK
[29]. Ectopic MEK/ERK is sufficient to drive excess vul-
val induction [29] and inhibition of MEK alone is
Figure 1 MCP110 and MCP116 but not MCP146 inhibit the Ras/LET-60-induced Muv phenotype. A. Representative images of untreated
wild-type animals (WT phenotype with normal vulva (arrowhead) but no ventral protrusions); animals harboring constitutively activated Ras
treated with vehicle only (Muv phenotype; arrows mark ventral protrusions formed by pseudovulvae); the same strain following treatment with
MCP110 (20 μM) (WT phenotype, as indicated by lack of ventral protrusions). B. Animals harboring constitutively activated Ras as in Panel A were
treated with either vehicle (DMSO) or MCP110, MCP116, MCP146 or negative control MCP122 (3, 10 or 20 μM; higher concentrations precipitated
out of solution). The Y-axis indicates the percentage of MCP-treated animals with a Muv phenotype, normalized to vehicle-treated animals. Data
were analyzed by three-way ANOVA. (***) and (*) indicate p values of < 0.0001 and < 0.05, respectively.
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sufficient to block the MEK/ERK-induced phenotype
[25]. Thus, MEK/ERK animals should also be resistant
to MCP compounds, which are believed to act by dis-
rupting the upstream Ras/Raf interface. As predicted,
MEK/ERK animals were also resistant to MCP110,
MCP116 and MCP146 (Figure 2B), with no significant
Muv differences observed in MCP- versus vehicle-trea-
ted animals. These results show that MCP110 and
MCP116 target the Ras-Raf-MAPK pathway downstream
of Ras and upstream of MEK.
MCP compounds inhibit activated Raf
To determine if MCP compound activity is due to
blocking Raf, we compared the Muv phenotype of
RafAA animals grown in the presence of MCP com-
pounds or vehicle. Surprisingly, RafAA animals were
sensitive to the action of MCP110, and, to a lesser
extent, to MCP116 and the poorly active derivative
MCP146 (Figure 3). Reversion of the Muv phenotype in
these animals by MCP110 was dose-dependent and
occurred with similar potency as in the Ras strain. This
result suggested that MCP110 inhibition of Muv induc-
tion occurred at the level of Raf, rather than Ras. How-
ever, this Raf ortholog, although constitutively activated
and sufficient to drive the Muv phenotype, still includes
the Ras-interacting domains RBD and CRD [28].
Whether RafAA is completely Ras-independent is
unclear [32,33]. It is possible that, in C. elegans, full
Figure 2 MCP110 and derivatives do not inhibit the Muv phenotype induced by activation of the Ras-Raf-MAPK pathway downstream
of Raf. Animals were treated, data were analyzed and results are presented as described in the legend to Figure 1B. A. Ets and B. activated MEK/
ERK.
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activation of LIN-45AA requires a contribution from
endogenous Ras. Further, given that MCP116 robustly
inhibited Ras but not Raf induction of the Muv pheno-
type, it is possible that they do not bind in exactly the
same manner to the Ras/Raf [Ras/RafAA] interface. We
and others have attempted unsuccessfully to generate
transgenic C. elegans strains carrying novel Raf/LIN-45
mutants predicted to be independent of Ras and lacking
the Raf RBD and CRD. Transgenic animals harboring
such constructs should definitively answer the questions
of whether MCP110 reverts the Muv phenotype of
RafAA-expressing animals by acting at the level of Ras
or Raf, or whether MCP110 and MCP116 bind to Ras
or Raf in the same manner. These questions will likely
require structural information that is not yet available.
MCP110 inhibits the physical interaction between Ras and
Raf in mammalian cells
Another possibility to explain the ability of MCP110 to
inhibit the Muv phenotype of RafAA-expressing animals
is that this action does not occur as a consequence of
disruption of the Ras/Raf interface. To confirm that
MCP110 can in fact disrupt the Ras-Raf interaction, we
turned to mammalian cells where biochemical analyses
are more tractable.
The initial screening strategy for MCP compounds
relied on the ability of the screened library components
to separate the interaction of Ras and Raf in a yeast
two-hybrid assay utilizing full-length versions of H-Ras
and Raf-1 [18,20]. It remains unclear if the activity of
MCP1, the originally identified MCP pharmacophore,
relied on interaction with the Ras or the Raf protein
interface. To address this question for MCP110, we took
advantage of the fact that activated, GTP-bound Ras
binds to Raf via interaction of its own effector domain
(core residues 32-40 as well as flanking sequences) with
the Ras binding domain (RBD) and cysteine-rich domain
(CRD) of Raf. The affinity of the RBD of Raf for active
Ras-GTP has been exploited to generate a widely used
probe for this interaction, designated Raf-RBD, which is
composed of residues 51-131 in the amino-terminal reg-
ulatory region of Raf-1. A GST-fusion protein of Raf-
RBD [GST-Raf-RBD] has long been used as an affinity
for pulldown assays to retrieve and quantitate the levels
of activated Ras in cell lysates [34,35]. More recently, we
have used the ability of Ras to recruit YFP- or GFP-
tagged Raf-RBD as a visual probe for the subcellular
localization of active Ras [36,37]. In each case, the read-
out is dependent on the physical interaction between
Ras and Raf-RBD. Thus, to further understand the
mechanism of action of MCP110 we analyzed its ability
to disrupt the interaction between activated Ras and the
Raf-RBD in a cell-based system.
We first performed pulldown assays in NIH 3T3 cells
transiently transfected with both a constitutively active
form of Ras and GST-Raf-RBD. Briefly, GST-Raf-RBD
coupled to GSH-agarose beads was used to retrieve
active Ras from lysates of cells treated with vehicle or
Figure 3 MCP110 inhibits the Raf-AA Muv phenotype. Animals expressing a constitutively activated Raf/LIN-45 protein were treated with
vehicle (DMSO) or MCP110 as in Figure 1B. Bar graphs show the percentage of MCP-treated animals with a Muv phenotype, normalized to
vehicle-treated animals. (***) and (**) indicate p-values of < 0.0001 and < 0.01, respectively.
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MCP110 (see Methods), and the co-precipitated Ras was
then detected by immunoblot analysis. We observed
that the physical interaction between Ras and the Raf-
RBD was disrupted by MCP110 in a dose-dependent
manner, but not by the vehicle negative control (Fig.
4A, top panel). To confirm that less Ras was retrieved
in the presence of MCP110 due to less effective interac-
tion of Ras with the Raf-RBD rather than due to poor
expression, we also assessed the total levels of Ras from
equivalent amounts of lysates. We observed that Ras
protein expression did not decrease upon MCP110
treatment (Fig. 4A, lower panel), indicating that Ras was
still available for pulldown but was not retrieved.
If MCP110 decreased the physical interactions
between Ras and Raf, it should also decrease down-
stream signaling through the Ras-Raf-MAPK pathway.
We therefore examined the levels of phosphorylated
ERK1/2 (p-ERK1/2) by immunoblotting with a phospho-
specific antibody for ERK1/2 proteins that are
phosphorylated at threonine 202 and tyrosine 204.
Consistent with the dose-dependent inhibition of the
Ras-Raf interaction, p-ERK levels were also reduced in a
Figure 4 MCP110 inhibits Ras/Raf interaction and signaling to ERK in mammalian cells. A. Pulldown assay for Ras-Raf interaction. Pulldowns
of active Ras bound to Raf-RBD were done using GST-Raf-RBD as described in Methods. NIH 3T3 cells were treated with vehicle or MCP110 (3,
10 and 30 μM) before and after lysis. Ras was detected by immunoblotting with anti-Ras antibody. Both Raf-RBD-bound Ras (Ras-GTP, upper
panel) and total Ras in the lysates (lower panel) are shown. MCP110 disrupted the Ras/Raf interaction in a dose-dependent manner; numbers
shown below panels indicate quantitation of Ras pulldown by densitometry, normalized to vehicle control. B. Western blot analysis for active,
phospho-ERK1/2. The same lysates from cells depicted in panel A above were immunoblotted for phospho-ERK1/2 (P-ERK, upper panel) and for
total ERK1/2 (total ERK, lower panel). Numbers shown below PERK panel indicate quantitation by densitometry, normalized to vehicle control.
MCP110 decreased phospho-ERK1/2 in a dose-dependent manner.
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dose-dependent manner upon addition of MCP110 but
not vehicle (Fig. 4B, upper panel), while the total levels
of ERK remained unaffected (Fig. 4B, lower panel).
Together, these results indicate that MCP110 can inhibit
the physical interaction between Ras and Raf, as well as
at least one functional consequence of that interaction,
namely signaling to the downstream effector MAP
kinases, ERK1/2. They also demonstrate that interaction
of Ras with the Raf-RBD alone can be impaired by
MCP110, consistent with the possibilities that the
MCP110-mediated inhibition of the Muv phenotype
induced in C. elegans by the LIN-45AA mutant Raf
ortholog that retains the RBD may be due to MCP110
binding to either Ras/LET-60 or to Raf/LIN-45. These
possibilites cannot be distinguished at present.
MCP110 impairs localization of Raf-RBD to the plasma
membrane in cells expressing constitutively active Ras
To corroborate our findings that MCP110 disrupted the
physical interaction of Ras with the Raf-RBD, with a
consequent functional impairment of downstream sig-
naling, we wished to evaluate this interaction by another
approach. As mentioned above, one biologically relevant
method for doing so is to visually monitor the localiza-
tion of a fluorescently tagged Raf-RBD. We have pre-
viously utilized Raf-RBD tagged with yellow fluorescent
protein (YFP-Raf-RBD) to probe the subcellular localiza-
tion of activated Ras [36]. We therefore used this probe
in NIH 3T3 cells treated with vehicle or MCP110 to
compare the localization of the Raf-RBD with that of a
constitutively active, HA-tagged Ras, which was detected
by Alexa-Fluor594-conjugated secondary antibody direc-
ted against the epitope tag. Cells were scored according
to whether the YFP-Raf-RBD probe was localized to one
of three major subcellular distributions: primarily mem-
branes including plasma membrane; internal membranes
and cytosol; or cytosol and nucleus.
In cells expressing the YFP-Raf-RBD probe along with
empty vector, YFP-Raf-RBD displayed a diffuse distribu-
tion throughout the cytosol and nucleus (representative
images are shown in Fig. 5A and quantitation is shown in
Fig. 5B). In stark contrast but as expected [36], co-expres-
sion of constitutively activated Ras resulted in exclusion of
YFP-Raf-RBD from the nucleus and strong recruitment of
Raf-RBD to membrane sites of Ras localization such as the
plasma membrane and internal membrane compartments
(Figs. 5A and 5B, vehicle treatment). Consistent with the
ability of MCP110 to dose-dependently reduce the amount
of Ras pulled down by GST-Raf-RBD (Fig. 4A, upper
panel), it also dose-dependently impaired the recruitment
of YFP-Raf-RBD to sites of activated Ras (Fig. 5A,
MCP110 treatment). Indeed, with increasing doses of
MCP110, YFP-Raf-RBD was restored to the cytosol and
the nucleus (Fig. 5A, top row, and Fig. 5B, Ras + MCP110)
even as the co-expressed active Ras remained membrane-
bound and nuclear-excluded (Fig. 5A, middle row). These
results are also consistent with MCP110 disruption of the
physical interaction between Ras and Raf.
Discussion
MCP110 and MCP116 act downstream of Ras/LET-60 and
upstream or at the level of Raf/LIN-45
Putative Ras-Raf interaction inhibitors such as MCP1 or
derivatives based on MCP1, such as MCP110, have been
shown previously to inhibit Ras-induced transcriptional
reporter activity, cell migration, morphological and growth
transformation as well as tumorigenicity in nude mice
[20,21,23]. However, although these small molecules were
originally identified via a yeast two-hybrid screen for inhi-
bitors of interactions between H-Ras and Raf-1 [18-20],
whether their biological activities in mammalian cells are
due to physical disruption of this interaction has not been
shown. Further, there have been conflicting reports in the
literature as to whether the presence of mutationally acti-
vated and therefore Ras-independent B-Raf [B-Raf
(V600E)] confers resistance to inhibition by MCP com-
pounds [20,23]. However, these studies focused on differ-
ent MCP analogs (MCP1 vs MCP110) and evaluated their
actions in distinct B-Raf(V600E)-expressing melanoma
lines, which could explain the different results. Therefore
it was also not certain whether MCP compounds as a
group act at the level of Ras or Raf.
Here we have used C. elegans as a genetic tool to
investigate the level of the Ras-Raf-MAPK pathway at
which MCP110 and its novel derivatives MCP116 and
MCP146 act. The C. elegans orthologs are highly con-
served with their mammalian counterparts, although the
output of this pathway in C. elegans is vulval fate speci-
fication, and when hyperinduced leads to a Muv pheno-
type. We have shown here that MCP110 and MCP116
but not MCP146 inhibit the Muv phenotype driven by
the C. elegans ortholog of Ras, but fail to inhibit the
Muv phenotype driven by downstream elements of the
pathway including MEK/MAPK and an Ets-like tran-
scription factor. We have used this model previously to
validate epistatically the actions of the MEK inhibitor
U0126 [25,31], thus supporting the use of the Muv-dri-
ven phenotype caused by genetic lesions in elements of
the Ras-Raf-MAPK pathway as a readout for pharmaco-
logical inhibition of the pathway. This phenotype has
also been used previously by others to demonstrate spe-
cificity of first-generation farnesyltransferase inhibitors
(FTIs) gliotoxin and manumycin, which target enzymatic
modification of Ras, and thus can block the Ras Muv
phenotype but not the Ets Muv phenotype [31].
Our analysis showed that MCP110 and MCP116
exerted activity against the Muv phenotype of constitu-
tively activated RafAA animals, which was unexpected
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Figure 5 MCP110 impairs recruitment of Raf-RBD to subcellular locations of active Ras. A. Recruitment of YFP-Raf-RBD to sites where Ras is
localized, as detected by fluorescence microscopy. NIH3T3 cells transiently expressing both HA-tagged active Ras and YFP-Raf-RBD were treated with
vehicle or MCP110. Shown are representative images of cells quantitated in Panel B below. In the absence of active Ras (v.o.), YFP-Raf-RBD (green)
was localized diffusely throughout the cytoplasm and nucleus, whereas in the presence of active Ras, the Raf-RBD probe was recruited to the
plasma membrane and, like Ras (red), was nuclear-excluded ("vehicle” panels). Increasing concentrations of MCP110 increasingly shifted the
YFP-Raf-RBD probe from the plasma membrane to the cytosol and to internal membranes and finally to both cytosol and nucleus, whereas Ras
remained membrane-associated and nuclear-excluded. These results indicate dose-dependent disruption of the Ras/Raf-RBD interaction by
MCP110. B. Quantification of the distribution of YFP-Raf-RBD subcellular localization. Cells treated and analyzed as described in Methods and depicted
qualitatively in Panel C were binned according to whether the YFP-Raf-RBD probe accumulated primarily in the cytosol, or cytosol + internal
membranes, or at the plasma membrane and was nuclear-excluded. MCP110 dose-dependently disrupts the ability of Ras to recruit Raf-RBD.
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since RafAA had been reported to be Ras-independent
and therefore should not be sensitive to disruption of
the Ras-Raf interaction. Epistasis analysis involving these
transgenes, in combination with loss-of-function muta-
tions in upstream elements, suggested that their Muv
phenotype is independent of Ras activity [32], but this
was not proven conclusively since Ras/LET-60 itself was
still present and functional. The mechanisms by which
Raf and LIN-45 are activated have been extensively
reviewed elsewhere [28,38,39], and it is clear that
human and worm orthologs have similar regulatory
mechanisms. However, the significant pharmacological
inhibition of the activated Raf/LIN-45-driven Muv phe-
notype by MC110 seen hereimplies that the mechanisms
by which LIN-45 is activated may still require Ras-Raf
interaction. Indeed, this protein retains both the Ras-
binding domain and CRD, thus leaving room for MCP
action on the Ras-Raf interface. Our attempts, like those
of many others in the C. elegans field, to generate more
informative lin-45 transgenes were unsuccessful, so
whether a truly Ras/LET-60-independent form of hyper-
activated Raf/LIN-45 would be resistant to inhibition by
MCP110 or MCP116 remains to be determined.
The discrepancies in previous observations of MCP
activity leaves room to consider that the selectivity of
these compounds for either Ras or Raf may rely in part
on the model system or cell context. The ability of
MCP110 and MCP116 to inhibit the Muv phenotype in
animals expressing activated Ras/LET-60 may be due to
the 86% identity of LET-60 shared with N-Ras in the
first 164 amino acids, which allows LET-60 to possess
all the biochemical functions of Ras proteins in mam-
mals [40]. Conversely, some subtle isoform differences
may also account for apparently discordant results
between studies that do not evaluate precisely the same
players [41].
While C. elegans does not replace mammalian cell cul-
ture models or higher organisms for in vivo studies, the
use of a living organism for pharmacological studies,
especially one like C. elegans that has been extensively
characterized at the developmental and behavioral levels,
can also lead to the detection of toxicity and off-target
activity early in the drug discovery process, as well as to
genetic identification of the target of unexpected biolo-
gical activities [24]. The availability of additional trans-
genes for study will further increase the utility of this
model system for drug discovery and development.
MCP110 is a true protein-protein inhibitor of the Ras-Raf-
RBD interaction
The original screen for MCP compounds, described in
detail in [18,20], involved a modification of the yeast
two-hybrid assay, which is a standard and powerful
technique to detect protein-protein interactions and was
the first method used to identify the interaction between
Ras and Raf in live cells [42]. The technique, performed
in this case in a hyperpermeable strain of yeast to
enhance penetration of the cell wall by small molecules
[18], detects these interactions by the transcriptional
transactivation of a dual reporter system, and thus it is
important for the interactions being analyzed to take
place in the cell nucleus. Normally, Ras is post-transla-
tionally modified by farnesylation at its C-terminus for
membrane targeting and biological activity, but in order
to produce more functional Ras (bait) in the nucleus,
the C-terminal modification motif was mutated to
become insensitive to plasma membrane targeting [18].
The alteration of Ras localization to fit the purpose of
the screen may have had an impact on the outcome,
especially since it is thought that Raf interacts differently
with farnesylated vs nonfarnesylated Ras proteins [43].
In addition, compounds registering positive in this
screen may have had allosteric effects on regions of Raf
not directly interacting with Ras.
To add another layer of complexity to the potential
mechanism of action (MOA) of MCP110 and related
compounds, as well as to experimental approaches to
identifying inhibitors of Ras-Raf and to testing and vali-
dating inhibitor MOA, the activation of Raf-1 involves a
series of steps involving membrane translocation,
dephosphorylation at negative regulatory sites, and sub-
sequent phosphorylation at activating sites in the kinase
domain [44]. Activation of B-Raf is similar but not iden-
tical, and currently there is much attention being paid
to possible influences of Raf-1 on B-Raf and vice versa
[45-48]. Given that localization of Ras and the complex
regulation of Raf are key determinants for activation of
the signaling cascade, it is also possible that the original
screen could have selected lead candidates affecting Ras
or Raf interaction with other proteins that are positive
regulators of the pathway. Several scaffolding proteins
interact with members of the Ras-Raf-MAPK pathway
to regulate the pathway by effects on protein localization
or protein-protein interactions [49]. For example, SUR-8
is an evolutionarily conserved scaffold protein that is a
positive regulator required for optimal Ras-MAPK sig-
naling [50,51]. SUR-8 facilitates Ras-Raf complex forma-
tion [52], whereas reduction of SUR-8 suppresses
activated Ras-mediated signaling in C. elegans [50,52].
The formation of a ternary complex of SUR-8 with acti-
vated Ras and Raf suggests that SUR-8 could also be a
target of MCP110 activity, although the ability of
MCP110 to impair the interaction of Ras with just the
Raf-RBD interaction indicates that SUR-8 would not be
an exclusive target.
An important finding of this study was the detection
of MCP110-mediated disruption of the physical Ras-Raf
interaction, providing evidence for the first time that
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MCP110 significantly disrupts the protein-protein inter-
face involving full-length H-Ras and the Raf-RBD in
mammalian cells. This indicates that MCP110 can act as
a true PPI inhibitor. Whether it also disrupts the inter-
action of K-Ras and N-Ras with Raf-RBD remains to be
determined. Also remaining to be determined is whether
it shows selectivity for disruption of interactions of Ras
with the different Raf isoforms. The strong association
of Raf-RBD with Ras-GTP versus Ras-GDP [53] sup-
ports MCP110 disruption of the Ras-Raf complex, but
the selectivity of MCP110 to disrupt interactions
between Ras and Raf versus other GTPase/RBD pairs
has also not yet been determined. Given that it is pre-
sently unclear whether MCP110 binds to Ras, to Raf-
RBD or both, it would also be of interest to evaluate the
ability of MCP110 to disrupt the interaction of the
RBDs of other GTPases and their effectors. For example,
RBDs of Ral GEFs (RalGDS, Rgl1-3) can interact with
Ras as well with the Rap1A GTPase [54-56]. Whether
MCP110 can also disrupt the interaction of Ras with
RalGEF RBDs or Rap1A with Raf-RBD will be important
to determine. Additionally, the effector domain of the
Ras-related GTPase Rit provides a similar surface to
that of Ras [41], and may thus also be disruptable by
MCP110, MCP116 or related compounds. Finally, why
MCP110 and MCP116 did not display the same ability
to inhibit the RafAA Muv phenotype is currently
unclear. The availability of structural information on
complexes of MCP110 and of MCP116 with Ras-Raf
would be of great assistance in making predictions
about the most fruitful avenues to pursue in these
directions.
Conclusions
Here we used both mammalian cell culture studies and
the genetically tractable C. elegans in vivo model to
investigate the activity of putative Ras/Raf interaction
inhibitors. We dissected the pathway and were able to
determine that MCP compounds act downstream of
Ras/LET-60 and upstream or at the level of Raf/LIN-45,
thereby providing additional proof-of-principle for the
use of C. elegans as a simple and attractive model for
the characterization of novel or already isolated Ras
pathway inhibitors. The work presented here has con-
tributed to a better understanding of the mechanism of
action of putative Ras/Raf interaction inhibitors based
on the MCP110 pharmacophore. In addition to support-
ing previous conclusions that MCP110 significantly inhi-
bits the signals caused by activated Ras in vitro and in
vivo, we have been able to narrow the requirements for
its activity by successfully using it to disrupt the Ras/
Raf-RBD interaction. Given these results, it will be inter-
esting to see if more focused screens involving Ras and
the Raf-RBD can identify additional potent and selective
Ras/Raf interaction inhibitors.
Methods
C. elegans strain maintenance and culturing conditions
Strain maintenance and nomenclature are as described
[57,58]. Strains were cultured on 2% NG agar plates
seeded with E. coli strain OP50. SD418 gaIs37 (mek-2
(gf)+mpk-1(gf))strain was maintained at 15°C and
switched to 25°C to induce its conditional hyper-
induced phenotype.
Briefly, activated Ras results from an in situ mutation
in LET-60/Ras that causes a G13E change equivalent to
G13E in human Ras, which is functionally similar to the
well known G12V activating mutation [27]. Activation
of Raf is a multistep process in which several regulatory
residues are modified to regulate its kinase activity.
Transgenic alteration of the conserved Akt negative reg-
ulatory sites from serine to alanine at residues 312 and
453 ("AA”) in Raf (RafAA) leads to a hyper-induced
phenotype comparable to that conferred by activated
Ras [28,33]. Activated MEK/ERK results from transgenic
expression of both activated Drosophila MEK and
activated C. elegans ERK (MPK-1), all driven by a heat-
shock promoter. Consequently, the MEK/ERK Muv
phenotype is temperature-sensitive, such that animals
are grown at 25°C to induce a Muv phenotype, but are
wild type at 15°C [29]. Finally, “Ets” refers to loss of the
LIN-1/Ets transcription factor function. LIN-1 inhibits
vulval fate, so LIN-1 loss results in hyper-induction [30].
Drug assays and quantification of the multivulva (Muv)
phenotype
We have described in detail the experimental proce-
dures for C. elegans drug treatments and phenotype
quantification [25]. Briefly, experiments were performed
in 6-well tissue culture plates in which only the four
corner wells were filled with 3 ml of 2% NG agar. Either
vehicle alone (dimethylsulfoxide; DMSO) or vehicle plus
experimental drug (MCP110, MCP116, or MCP146) was
diluted in M9 buffer and applied in a defined volume to
the agar in each well to achieve the final dose. Plates
absorbed the drug overnight, then were seeded with 90
μl of OP50 overnight culture and allowed to grow for
24 hours to ensure a suitable bacterial lawn.
To obtain a population of treated animals that was
developmentally synchronous, we harvested embryos
during a narrow time frame. For each strain and drug,
12-15 adult hermaphrodites laid eggs for 3 hours, after
which the parents were removed.
Animals to be assayed were exposed to drug through-
out development. Animals harboring activated Ras, Raf
and MEK/MAPK were scored as early adults using the
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dissecting microscope. Animals harboring activation of
the Ets-like transcription factor were scored at the 4th
larval stage (L4) because adult pseudovulvae were too
distorted to quantify clearly [25]. For DIC microscopy,
animals were mounted on slides in M9 buffer containing
5 mM sodium azide.
To reproducibly score the outcome of drug assays, we
used a specific set of phenotypic criteria. First, we cate-
gorized animals in a binary assay as Muv or non-Muv,
depending on the presence of the ectopic pseudovulvae
that indicate hyper-induction of vulval tissue. Second,
we quantified the number of ectopic pseudovulvae. Each
genotype assayed had a different baseline for degree of
hyper-induction, and therefore for each genotype the
baseline was re-established such that animals treated
with the experimental drug were normalized to the level
of hyper-induction in animals treated with vehicle.
Statistical analyses
In order to assess the overall effects of strain, concentra-
tion, and drug, we used a three-way ANOVA model
with fixed main effects for strain, concentration and
drug, all pairwise and three-way interactions to compare
the mean proportions of standardized MUV phenotype
scores. The three-way interaction was determined to be
statistically significant at the 0.05 level (p < 0.0001), sup-
porting the significance of the dose-dependent effects of
MCP compounds that we observed in Ras/LET-60 and
Raf/LIN-45 animals.
Cell culture and transfections
NIH 3T3 mouse fibroblasts were grown in DMEM
(Sigma-Aldrich, St. Louis, MO) supplemented with 10%
GCS calf serum (GIBCO/Invitrogen, Carlsbad, CA) and
1% penicillin/streptomycin and maintained in 5% CO2 at
37°C. Cells were plated the day before transfection at a
density of 200,000 cells per 60 mm dish or 100,000 cells
per 35 mm dish (or in a 6-well plate), for the pulldown
and co-localization assays, respectively. For pulldown
assays, pcDNA3.1 (vector only, v.o.) or pcDNA3.1 encod-
ing activated H-Ras(12 V) were transfected transiently into
cells using TransIT-LT1 Transfection reagent (Mirus,
Madison, WI) according to the manufacturer’s specifica-
tions. For co-localization assays, pEYFP-Raf-RBD was
cotransfected with either empty pCGN-HA vector (v.o.) or
pCGN-HA encoding activated H-Ras(12 V). Immediately
after transfection, a designated amount of either DMSO
vehicle or MCP110, MCP116 or MCP146 was added at 3,
10 or 30 μM and further assays were performed after 48 h.
Pulldown assays and immunoblotting
Transiently transfected NIH 3T3 cells (see above) were
lysed in 400 μl of freshly prepared Magnesium Lysis
Buffer (MLB) combined with protease inhibitor cocktail
(BD BaculoGold, BD Biosciences Pharmingen, San Jose,
CA). Lysates were cleared by centrifugation at 12,000
rpm for 10 min at 4°C, and protein concentration was
measured in a Bradford Assay (Bio-Rad Laboratories,
Hercules, CA). GST fusion proteins of the Raf-1 Ras
binding domain (GST-Raf-RBD) were prepared from
pGEX-2T encoding Raf-RBD as described previously
[35,59]. Empty vector pGEX-2T plasmid encoding GST
alone was a negative control. A total of 100 μg of
MCP110 pre-treated protein lysate was incubated with
10 μl of glutathione agarose beads (Sigma) previously
coupled to GST alone or to GST-Raf-RBD. Parallel to
the incubation of lysate with beads, additional drug was
added and the pulldown reaction was performed in a
final volume of 500 μL, rocking for 1 h at 4°C. Proteins
bound to beads were collected, washed three times in
lysis buffer and eluted in non-reducing protein sample
buffer. Pulldown samples and total protein were ana-
lyzed by SDS-polyacrylamide gel electrophoresis and
western blotting.
For immunoblotting, membranes were blocked in 5%
non-fat dry milk and incubated overnight with primary
antibodies diluted to 1:3,000 for H-Ras (146, Quality
Biotech, NJ), 1:500 for p-ERK (Cell Signaling Technol-
ogy, Danvers, MA) or 1:2,000 total ERK (Cell Signaling
Technology) dilution, overnight at 4°C. Membranes
were washed and incubated for 1 h in a 1:30,000 dilu-
tion of anti-mouse or anti-rabbit IgG-horseradish perox-
idase antibody (GE Healthcare/Amersham, Piscataway,
NJ), washed extensively with TBS-T and developed with
SuperSignal West Dura Extended Duration substrate
(Thermo Scientific, Rockford, IL).
Inmunofluorescence assay for Ras recruitment of Raf-RBD
probe
NIH 3T3 cells were grown on coverslips, transiently
transfected as above, and treated with MCP110 for 48 h
before fixation in 3.7% formaldehyde, permeabilization
with 0.5%Triton and blocking in 2% BSA for 1 h at
room temperature. Coverslips carrying fixed cells were
incubated in a 1:200 dilution of anti-HA antibody (Cov-
ance, Emeryville, CA) for 1 h, followed by two washes in
1× Phosphate Buffered Saline (PBS), an additional incu-
bation with a 1:1,000 dilution of AlexaFluor594 anti-
mouse conjugated secondary antibody (Molecular
Probes, Eugene, OR) for 30 min and washed three times
with 1× PBS. Coverslips were mounted into a glass
microslide with ProLong Gold antifade (Invitrogen/
Molecular Probes, Eugene, OR) mounting medium and
cells were visualized by confocal microscopy.
List of abbreviations
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